Glucosamine therapy for osteoarthritis: An update

Journal of Rheumatology

Volumn 34, Issue 9, 2007, Pages 1787-1790

  Towheed, Tanveer E ^a   Anastassiades, Tassos ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE; GLUCOSAMINE SULFATE; GLYCOSAMINOGLYCAN; MANNOSAMINE; PLACEBO;

ARTICULAR CARTILAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNOVIAL FLUID LEVEL; EDITORIAL; HORSE; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANIMALS; DISEASE MODELS, ANIMAL; GLUCOSAMINE; HUMANS; OSTEOARTHRITIS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 35948940759     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (35)

1. Towheed TE, Anastassiades T. Glucosamine therapy for osteoarthritis. J Rheumatol 1999;26:2294-97.
2. Towheed TE, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005;2:CD002946.
3. McAlindon T. Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin North Am 2003;29:789-801.
4. McAlindon TE. Nutraceuticals: do they work and when should we use them? Best Pract Res Clin Rheumatol 2006;20:99-115.
5. Cibere J, Kopec JA, Thorne A, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 2004;51:738-45.
6. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999;26:2423-30.
7. Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology Oxford 2002;41:279-84.
8. McAlindon T, Formica M, LaValley M, Lehmer M, Kabbara K. Effectiveness of glucosamine for symptoms of knee osteoarthritis: Results from an Internet-based randomized double-blind controlled trial. Am J Med 2004;117:643-9.
9. Rindone JP, Hiller D, Collacott E, Nordhaugen N, Arriola G. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000;172:91-4.
10. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808.
11. Adebowale AO, Cox DS, Liang Z, Eddington ND. Analysis of glucosamine and chondroitin sulfate content in marketed products and the caco-2 permeability of chondroitin sulfate raw materials. J Am Nutraceutical Assoc 2000;3:37-44.
12. Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 1999;25:379-95.
13. Joint remedies. Consum Rep 2002;67:18-21.
14. Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002;29:2407-9.
15. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M. N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes. J Immunol 2001;166:5155-60.
16. Terry DE, Rees-Milton K, Smith P, et al. N-acylation of glucosamine modulates chrondocyte growth, proteoglycan synthesis, and gene expression. J Rheumatol 2005;32:1775-86.
17. Basleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998;6:427-34.
18. Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991;41:542-5.
19. Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 2003;11:424-32.
20. Largo R, Alvarez-Soria MA, Diez-Ortego I, et al. Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003:11:290-8.
21. Nakamura H, Shibakawa A, Tanaka M, Kato T, Nishioka K. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 2004;22:293-9.
22. Varghese S, Theprungsirikul P, Sahani S, Hwang N, Yarema KJ, Elisseeff JH. Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression. Osteoarthritis Cartilage 2007;15:59-68. Epub 2006 Jul 18.
23. Friedman SJ, Skehan P. Membrane-active drugs potentiate the killing of tumor cells by D-glucosamine. Proc Natl Acad Sci USA 1980;77:1172-6.
24. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 1991;266:4706-12.
25. Sandy JD, Thompson V, Verscharen C, Gamett D. Chondrocyte-mediated catabolism of aggrecan: evidence for a glycosylphosphatidylinositol-linked protein in the aggrecanase response to interleukin-1 or retinoic acid. Arch Bioch Biophys 1999;367:258-64.
26. Patwari P, Kurz B, Sandy JD, Grodzinsky AJ. Mannosamine inhibits aggrecanase-mediated changes in the physical properties and biochemical composition of articular cartilage. Arch Biochem Biophys 2000:373:258-65.
27. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glucosamine HCL reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000;8:258-65.
28. D'Lima DD, Kuhn K, Lotz MK. Detection of apoptosis in cartilage in situ and in isolated chondrocytes. In: Sabatini M, Pastoureau P, DeCeuninck F, editors. Methods in molecular medicine: Cartilage and osteoarthritis. Vol 1: Cellular and molecular tools. Tolowa, NJ: Humana Press Inc.; 2004:275-89.
29. Uitterlinden EJ, Jahr H, Koevoet JL, et al. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage 2006;14:250-7. Epub 2005 Nov 18.
30. Biggee E, Blinn CM, McAlindon TE, Nuite M, Silbert JE. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis 2006;65:222-6.
31. Laverty S, Sandy JD, Celeste C, Vachon P, Marier JF, Plaas AHK. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum 2005;52:181-91.
32. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005;13:1041-9.
33. Persiani S, Rotini R, Rovati LC, Locatelli M, Roda A. Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in man [abstract]. Ann Rheum Dis 2005;64 Suppl III:490.
34. Mroz PJ, Silbert JE. Use of 3H-glucosamine and 35S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate. Arthritis Rheum 2004;50:3574-9.
35. Hopman W, Towheed TE, Gao Y, et al. Prevalence of and factors associated with glucosamine use in Canada. Osteoarthritis Cartilage 2006;14:1288-93.